LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 9 of 15: Cell count and normalized growth rate inhibition values within biological replicate 2. - Dataset (ID:20246)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Linsitinib | 1.11 | uM | LJP5 | 3 | O21 | 72 | hr | 2543 | 5291 | 5760 | 0.9184 | 0.8608 |
| SK-BR-3 | Linsitinib | 3.33 | uM | LJP5 | 1 | O20 | 72 | hr | 2543 | 4656 | 5734 | 0.8119 | 0.6745 |
| SK-BR-3 | Linsitinib | 3.33 | uM | LJP5 | 2 | O20 | 72 | hr | 2543 | 4355 | 5761 | 0.7559 | 0.5776 |
| SK-BR-3 | Linsitinib | 3.33 | uM | LJP5 | 3 | O20 | 72 | hr | 2543 | 4895 | 5760 | 0.8497 | 0.7421 |
| SK-BR-3 | Linsitinib | 10 | uM | LJP5 | 1 | O19 | 72 | hr | 2543 | 4207 | 5734 | 0.7336 | 0.5358 |
| SK-BR-3 | Linsitinib | 10 | uM | LJP5 | 2 | O19 | 72 | hr | 2543 | 4062 | 5761 | 0.7050 | 0.4872 |
| SK-BR-3 | Linsitinib | 10 | uM | LJP5 | 3 | O19 | 72 | hr | 2543 | 4182 | 5760 | 0.7259 | 0.5244 |
| SK-BR-3 | Ruxolitinib | 0.04 | uM | LJP5 | 1 | O18 | 72 | hr | 2543 | 5259 | 5734 | 0.9171 | 0.8577 |
| SK-BR-3 | Ruxolitinib | 0.04 | uM | LJP5 | 2 | O18 | 72 | hr | 2543 | 5369 | 5761 | 0.9319 | 0.8839 |
| SK-BR-3 | Ruxolitinib | 0.04 | uM | LJP5 | 3 | O18 | 72 | hr | 2543 | 5480 | 5760 | 0.9513 | 0.9170 |
| SK-BR-3 | Ruxolitinib | 0.12 | uM | LJP5 | 1 | O17 | 72 | hr | 2543 | 5451 | 5734 | 0.9506 | 0.9154 |
| SK-BR-3 | Ruxolitinib | 0.12 | uM | LJP5 | 2 | O17 | 72 | hr | 2543 | 5273 | 5761 | 0.9152 | 0.8553 |
| SK-BR-3 | Ruxolitinib | 0.12 | uM | LJP5 | 3 | O17 | 72 | hr | 2543 | 5572 | 5760 | 0.9672 | 0.9443 |
| SK-BR-3 | Ruxolitinib | 0.37 | uM | LJP5 | 1 | O16 | 72 | hr | 2543 | 5728 | 5734 | 0.9989 | 0.9981 |
| SK-BR-3 | Ruxolitinib | 0.37 | uM | LJP5 | 2 | O16 | 72 | hr | 2543 | 5205 | 5761 | 0.9034 | 0.8350 |
| SK-BR-3 | Ruxolitinib | 0.37 | uM | LJP5 | 3 | O16 | 72 | hr | 2543 | 5516 | 5760 | 0.9575 | 0.9277 |
| SK-BR-3 | Ruxolitinib | 1.11 | uM | LJP5 | 1 | O15 | 72 | hr | 2543 | 5227 | 5734 | 0.9115 | 0.8481 |
| SK-BR-3 | Ruxolitinib | 1.11 | uM | LJP5 | 2 | O15 | 72 | hr | 2543 | 5279 | 5761 | 0.9163 | 0.8571 |
| SK-BR-3 | Ruxolitinib | 1.11 | uM | LJP5 | 3 | O15 | 72 | hr | 2543 | 5287 | 5760 | 0.9178 | 0.8596 |
| SK-BR-3 | Ruxolitinib | 3.33 | uM | LJP5 | 1 | O14 | 72 | hr | 2543 | 5823 | 5734 | 1.0154 | 1.0263 |
| SK-BR-3 | Ruxolitinib | 3.33 | uM | LJP5 | 2 | O14 | 72 | hr | 2543 | 5434 | 5761 | 0.9432 | 0.9032 |
| SK-BR-3 | Ruxolitinib | 3.33 | uM | LJP5 | 3 | O14 | 72 | hr | 2543 | 5724 | 5760 | 0.9936 | 0.9892 |
| SK-BR-3 | Ruxolitinib | 10 | uM | LJP5 | 1 | O13 | 72 | hr | 2543 | 5625 | 5734 | 0.9809 | 0.9674 |
| SK-BR-3 | Ruxolitinib | 10 | uM | LJP5 | 2 | O13 | 72 | hr | 2543 | 5472 | 5761 | 0.9498 | 0.9145 |
| SK-BR-3 | Ruxolitinib | 10 | uM | LJP5 | 3 | O13 | 72 | hr | 2543 | 5423 | 5760 | 0.9414 | 0.9001 |